Indivior Pact Buys Addex Time For Progressing Dipraglurant And Pipeline

Addex Therapeutics says its licensing deal with Indivior to develop and commercialize its investigative addiction therapy ADX71441 'buys time' to find resources for progressing its own pipeline.

Steps
Addex To Use Indivior Drug Deal To Help Advance To Next Platform Stages • Source: Shutterstock

Swiss-based Addex Therapeutics – which has recently rebounded from a financial crisis – hopes a partnership deal with Indivior to develop new addiction treatments will give it adequate money, time and needed profiling to attract other partners for progressing its proprietary pipeline, notably its lead asset dipraglurant.

Founded in 2002, Addex is developing oral therapies for neurological disorders, targeting the GABAb receptor pathway in the brain. GABA...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip